Your browser is no longer supported. Please, upgrade your browser.
Settings
CGEN Compugen Ltd. daily Stock Chart
CGEN [NASD]
Compugen Ltd.
Index- P/E- EPS (ttm)-0.71 Insider Own12.00% Shs Outstand49.61M Perf Week13.33%
Market Cap168.67M Forward P/E- EPS next Y-0.84 Insider Trans0.00% Shs Float49.28M Perf Month4.62%
Income-36.20M PEG- EPS next Q-0.20 Inst Own18.20% Short Float4.69% Perf Quarter28.30%
Sales0.05M P/S3182.53 EPS this Y-55.00% Inst Trans-2.37% Short Ratio9.87 Perf Half Y21.43%
Book/sh0.74 P/B4.59 EPS next Y-13.50% ROA-60.90% Target Price8.10 Perf Year-22.73%
Cash/sh- P/C- EPS next 5Y- ROE-70.90% 52W Range2.25 - 5.40 Perf YTD36.00%
Dividend- P/FCF- EPS past 5Y-12.10% ROI-51.30% 52W High-37.04% Beta0.63
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin- 52W Low51.11% ATR0.27
Employees98 Current Ratio6.70 Sales Q/Q- Oper. Margin- RSI (14)63.76 Volatility6.81% 8.34%
OptionableYes Debt/Eq0.00 EPS Q/Q-26.30% Profit Margin- Rel Volume0.63 Prev Close3.35
ShortableYes LT Debt/Eq0.00 EarningsFeb 21 BMO Payout- Avg Volume234.15K Price3.40
Recom1.50 SMA2015.65% SMA5020.48% SMA2001.30% Volume147,663 Change1.49%
Feb-01-16Resumed Oppenheimer Outperform
Oct-15-15Initiated FBR Capital Outperform $14
Apr-23-15Resumed Jefferies Buy $11
Apr-21-15Initiated Oppenheimer Outperform $11
Feb-07-14Initiated MLV & Co Buy $14
Dec-28-09Reiterated Cantor Fitzgerald Buy $5 → $12
Jul-29-09Initiated Cantor Fitzgerald Buy $6.50
Feb-21-18 07:50AM  Compugen Ltd. to Host Earnings Call ACCESSWIRE +6.56%
07:31AM  Compugen reports 4Q loss Associated Press
07:07AM  Compugen Reports Fourth Quarter and Full Year 2017 Results PR Newswire
Feb-08-18 07:40AM  Wired News Compugen Reports Publication of Discovery and Validation of ILDR2 as A Novel Immune Checkpoint and Its Use for Auto-Immune Diseases ACCESSWIRE
07:00AM  Compugen Fourth Quarter and Full Year 2017 Conference Call Scheduled for Wednesday, February 21, 2018 at 10:00 AM ET PR Newswire
Feb-06-18 07:06AM  Compugen Announces Publication of the Discovery of ILDR2 as a Novel Immune Checkpoint and Its Use for the Treatment of Autoimmune Diseases in Two Back-to-Back Papers in The Journal of Immunology PR Newswire
Jan-18-18 07:00AM  Compugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid Tumors PR Newswire +18.18%
Jan-02-18 07:00AM  Compugen Announces Presentations at Three Upcoming Cancer Immunotherapy Conferences PR Newswire +8.00%
Dec-18-17 06:05PM  What You Must Know About Compugen Ltds (NASDAQ:CGEN) Financial Health Simply Wall St.
Dec-01-17 12:50PM  How Compugen Ltds (CGEN) EPS Dropped -53.2%, Did Its Industry Show Weakness Too? Simply Wall St.
Nov-15-17 12:37PM  Is It Too Late To Buy Compugen Ltd (CGEN)? Simply Wall St. +7.84%
Nov-07-17 08:20AM  Compugen Ltd. to Host Earnings Call ACCESSWIRE
07:17AM  Compugen reports 3Q loss Associated Press
07:10AM  Compugen Reports Third Quarter 2017 Results PR Newswire
Nov-06-17 09:23AM  Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers TheStreet.com
07:00AM  Compugen to Initiate Manufacturing of COM902, its Lead Anti-TIGIT Monoclonal Antibody PR Newswire
Nov-02-17 07:00AM  Compugen to Enter Research Collaboration With Mount Sinai on Novel Myeloid Immuno-Oncology Targets PR Newswire
Oct-26-17 07:00AM  Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month PR Newswire
Oct-25-17 07:00AM  Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET PR Newswire -5.80%
Oct-11-17 07:50AM  Corporate News Blog - Compugen Announces New Data Indicating Potential of CGEN-15032 ACCESSWIRE
Oct-10-17 08:30AM  Company News For Oct 10, 2017 Zacks
Oct-09-17 09:21AM  Flexion Shares Continue Rise After FDA Approval -- Biotech Movers TheStreet.com +7.04%
07:00AM  A New Immunomodulatory Target Discovered by Compugen Demonstrates Potential for First-in-Class Cancer Therapy PR Newswire
Oct-02-17 09:47AM  Compugen Ltd (CGEN): How Does It Impact Your Portfolio? Simply Wall St. -6.58%
Aug-07-17 07:00AM  Compugen to Present at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Next Month PR Newswire
Aug-04-17 07:40AM  Corporate News Blog - Paul Sekhri Appointed Chairman of Board at Drug Discovery Company Compugen ACCESSWIRE
Aug-02-17 10:43PM  Compugen reports 2Q loss Associated Press
07:22AM  Compugen Welcomes Paul Sekhri as its New Chairman of the Board PR Newswire
07:20AM  Compugen Reports Second Quarter 2017 Results PR Newswire
Jul-26-17 07:09AM  Compugen Discloses Updates to Collaborative Activities with Bayer in Immuno-Oncology PR Newswire
Jul-25-17 07:00AM  Compugen Announces Issuance of U.S. Patent for COM701, its Lead Immuno-Oncology Product Candidate PR Newswire +19.12%
Jul-24-17 07:00AM  Compugen Second Quarter 2017 Conference Call Scheduled for Wednesday, August 2, 2017 at 10:00 AM ET PR Newswire
Jun-05-17 09:00AM  Compugen Presents at ASCO COM701 Drug Combination Data with TIGIT and PD-1 Inhibitors in Preclinical Models PR Newswire -6.45%
May-31-17 07:00AM  Compugen Provides Update on COM701 and Upcoming Presentations PR Newswire
May-25-17 07:06AM  Compugen Announces Appointment of Dr. Michal Preminger to Board of Directors PR Newswire
May-23-17 07:00AM  Compugen to Present at Two Upcoming Investor Conferences in June PR Newswire
May-22-17 08:30AM  Compugen (CGEN) Worth a Look: Stock Adds 10.4% in Session Zacks +6.32%
May-09-17 09:15AM  Investor Network: Compugen Ltd. to Host Earnings Call Accesswire +8.22%
09:04AM  Compugen reports 1Q loss Associated Press
07:13AM  Compugen Reports First Quarter 2017 Results PR Newswire
May-04-17 07:00AM  Compugen to Present COM701 Checkpoint Product Candidate for Immuno-Oncology at ASCO PR Newswire
Apr-26-17 07:00AM  Compugen First Quarter 2017 Conference Call Scheduled for Tuesday, May 9, 2017 at 10:00 AM ET PR Newswire
Apr-25-17 03:27PM  ETFs with exposure to Compugen Ltd. : April 25, 2017 Capital Cube
Apr-07-17 04:08PM  ETFs with exposure to Compugen Ltd. : April 7, 2017 Capital Cube
Mar-28-17 07:14AM  Compugen Announces Lead Therapeutic Candidate COM902 for CGEN-15137/TIGIT Immuno-Oncology Program PR Newswire
Mar-22-17 07:00AM  Compugen to Present CGEN-15001 Autoimmune Product Candidate at Upcoming Conferences PR Newswire
Mar-20-17 08:58AM  Compugen Ltd. :CGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Capital Cube
08:58AM  Compugen Ltd. :CGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
Mar-14-17 02:51PM  Compugen Ltd. :CGEN-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Capital Cube
02:51PM  Compugen Ltd. :CGEN-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
Mar-08-17 07:00AM  Compugen Announces Addition of Prof. Miriam Merad to Its Scientific Advisory Board PR Newswire
Mar-02-17 07:00AM  Compugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery Methodology for Novel Immune Checkpoints at AACR PR Newswire
Feb-22-17 01:04PM  COMPUGEN LTD Financials
Feb-15-17 07:26AM  Compugen reports 4Q loss Associated Press
07:20AM  Compugen Reports Fourth Quarter and Calendar Year 2016 Results PR Newswire
Jan-30-17 07:00AM  Compugen Fourth Quarter and Yearend 2016 Conference Call Scheduled for Wednesday, February 15, 2017 at 10:00 AM EST PR Newswire
Jan-04-17 07:00AM  Compugen's CGEN-15001 Demonstrates Restoration of Immune Tolerance in Autoimmunity PR Newswire
Dec-20-16 10:27AM  What Makes Compugen Ltd. (CGEN) a Strong Sell?
Dec-18-16 04:26PM  Hedge Funds Are Dumping Voyager Therapeutics Inc (VYGR) at Insider Monkey
Dec-15-16 08:46AM  Is BioSpecifics Technologies Corp. (BSTC) A Good Stock To Buy Right Now? at Insider Monkey
Dec-13-16 10:23AM  Compugen Ltd. Value Analysis (NASDAQ:CGEN) : December 13, 2016
Dec-12-16 07:20AM  Compugen Ltd. breached its 50 day moving average in a Bullish Manner : CGEN-US : December 12, 2016
Dec-07-16 11:00AM  Compugen Announces Key Highlights from R&D Day PR Newswire
07:22AM  Compugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint PR Newswire
Dec-05-16 07:00AM  Compugen Appoints Senior Vice President Corporate and Business Development PR Newswire
Nov-22-16 07:32AM  Compugen Ltd. breached its 50 day moving average in a Bearish Manner : CGEN-US : November 22, 2016
Nov-21-16 07:00AM  Compugen to Present at 28th Annual Piper Jaffray Healthcare Conference in New York PR Newswire
Nov-11-16 11:45AM  Compugen Immune Checkpoint Program Demonstrates Potential for Development of New Cancer Immunotherapy Treatments PR Newswire
Nov-10-16 12:07PM  ETFs with exposure to Compugen Ltd. : November 10, 2016
Nov-09-16 11:22AM  Compugen Ltd. :CGEN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 9, 2016
Nov-07-16 07:14AM  Compugen reports 3Q loss
07:07AM  Compugen Ltd. Reports 3rd Quarter 2016 Financial Results PR Newswire
Nov-03-16 09:53AM  Compugen to Host R&D Day on December 7, 2016 in New York PR Newswire +5.26%
Oct-10-16 07:00AM  Compugen Third Quarter Financial Statements to be Released November 7, 2016 PR Newswire
Oct-07-16 07:00AM  Compugen to Present at the Annual Meeting of the Society for Immunotherapy of Cancer Next Month PR Newswire
Sep-28-16 09:41AM  ETFs with exposure to Compugen Ltd. : September 28, 2016
Sep-19-16 11:12AM  Compugen Ltd. Value Analysis (NASDAQ:CGEN) : September 19, 2016
Sep-16-16 08:38AM  Compugen Ltd. breached its 50 day moving average in a Bearish Manner : CGEN-US : September 16, 2016
Sep-07-16 09:30AM  Zacks.com featured highlights: Amarin, Compugen, Raptor Pharmaceuticals, ArcelorMittal and Hovnanian Enterprises
Sep-06-16 04:16PM  Explosive Stocks Under $10
08:40AM  Compugen (CGEN) Looks Good: Stock Adds 5.1% in Session
Aug-30-16 07:00AM  Compugen Discloses Development of Enhanced LINKS Platform Utilized for the Discovery of Myeloid Targets for Cancer Immunotherapy PR Newswire
Aug-22-16 11:14AM  ETFs with exposure to Compugen Ltd. : August 22, 2016
Aug-19-16 08:08AM  Compugen Ltd. breached its 50 day moving average in a Bullish Manner : CGEN-US : August 19, 2016
Aug-18-16 08:45AM  How Compugen (CGEN) Stock Stands Out in a Strong Industry
Aug-09-16 03:55AM  Compugen Ltd. :CGEN-IL: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016
Aug-05-16 11:13AM  Compugen Ltd. :CGEN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016
Aug-02-16 07:21AM  Compugen reports 2Q loss
07:01AM  Compugen Ltd. Reports 2nd Quarter 2016 Financial Results PR Newswire
Jul-29-16 08:32AM  Compugen Ltd. breached its 50 day moving average in a Bearish Manner : CGEN-US : July 29, 2016
Jul-21-16 07:00AM  Compugen Second Quarter 2016 Conference Call Scheduled for Tuesday, August 2, 2016 at 10:00 AM ET PR Newswire
Jul-08-16 08:26AM  Compugen Ltd. breached its 50 day moving average in a Bearish Manner : CGEN-US : July 8, 2016
Jun-22-16 10:00AM  Compugen Names Lead Therapeutic Candidate For CGEN-15029 Immuno-Oncology Program IND filing For COM701 Anticipated in 2017
08:08AM  Compugen Ltd. breached its 50 day moving average in a Bullish Manner : CGEN-US : June 22, 2016
07:09AM  Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program PR Newswire
Jun-15-16 07:00AM  Compugen to Present at JMP Securities Life Sciences Conference in New York PR Newswire
Jun-10-16 08:20AM  Compugen Ltd. breached its 50 day moving average in a Bearish Manner : CGEN-US : June 10, 2016
May-26-16 06:00AM  'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway
May-23-16 04:55PM  ETFs with exposure to Compugen Ltd. : May 23, 2016
07:00AM  Compugen to Present at the Jefferies Global Healthcare Conference in New York PR Newswire
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.